Pancreatic ductal
adenocarcinoma (PDAC) is one of the most fatal
malignancies and rapidly progressive diseases. Exosomes and long noncoding RNAs (lncRNAs) are emerging as vital mediators in
tumor cells and their microenvironment. However, the detailed roles and mechanisms of exosomal lncRNAs in PDAC progression remain unknown. Here, we aimed to clarify the clinical significance and mechanisms of exosomal
lncRNA 01133 (LINC01133) in PDAC. We analyzed the expression of LINC01133 in PDAC and found that exosomal LINC01133 expression was high and positively correlated with higher TNM stage and poor overall survival rate of PDAC patients. Further research demonstrated that
Periostin could increase exosome secretion and then enhance LINC01133 expression. In addition,
Periostin increased p-EGFR, p-Erk, and c-myc expression, and c-myc could bind to the LINC01133 promoter region. These findings suggested that LINC01133 can be regulated by
Periostin via EGFR pathway activity. We also observed that LINC01133 promoted the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of
pancreatic cancer cells. We subsequently evaluated the effect of LINC01133 on the Wnt/β-
catenin pathway and confirmed that LINC01133 can interact with
Enhancer Of Zeste Homolog 2 (EZH2) and then promote H3K27 trimethylation. This can further silence AXIN2 and suppress GSK3 activity, ultimately activating β-
catenin. Collectively, these data indicate that exosomal LINC01133 plays an important role in pancreatic
tumor progression, and targeting LINC01133 may provide a potential treatment strategy for PDAC.